Sanuwave Health Stock Price, News & Analysis

Sanuwave Health (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, has scheduled a conference call to discuss its Q2 2025 financial results on Friday, August 8, 2025, at 8:30 AM ET.

Investors can access the call via toll-free number 1-800-245-3047 or international number 1-203-518-9765 using Conference ID: SANUWAVE. A webcast link is also available. Presentation materials will be accessible on the company's investor relations website, and a replay will be available through August 29, 2025.

Sanuwave Health (NASDAQ: SNWV), a provider of FDA-approved wound care products, announced that CEO Morgan Frank will present at the 45th Annual Canaccord Genuity Growth Conference. The presentation is scheduled for August 13, 2025, from 9:30 to 9:55 a.m. ET at the InterContinental Hotel in Boston.

Sanuwave specializes in non-invasive medical systems for regenerative medicine, focusing on skin, musculoskeletal tissue, and vascular structure repair. The company's technology portfolio includes patented energy transfer technologies applied in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Sanuwave Health (NASDAQ:SNWV), a leading provider of FDA-approved wound care products, reported preliminary Q2 2025 revenues of $10.1-$10.2 million, marking its highest Q2 revenue in company history. This represents a 41-42% increase compared to Q2 2024.

The company has undergone significant commercial expansion, including the appointment of a new head of sales and commercial operations. By July, Sanuwave will have 13 sales representatives covering all national territories, plus a dedicated national accounts manager for larger opportunities. The first half of 2025 showed strong performance with a 50-51% revenue increase compared to the first half of 2024.

Full Q2 2025 results will be released around August 8th, 2025.

Sanuwave Health (NASDAQ:SNWV) has appointed Dustin Libby as Executive Vice President of Commercial Operations. Libby brings 20 years of medical device industry experience, with a strong track record in commercial growth and sales operations. His notable achievement includes scaling Abiomed's surgical business from $15M to over $500M in revenue as director of commercial operations. Libby's extensive experience includes leadership roles at Smith & Nephew, Arthrex, and Hill-ROM, where he managed sales enablement, operational strategy, KOL development, and product launches. CEO Morgan Frank emphasized Libby's experience in scaling teams and systems as crucial for Sanuwave's growth plans in the wound care market. Libby, who holds a B.S. in Product Design & Development from Keene State College, commenced his role on June 3, 2025.

Sanuwave Health (NASDAQ: SNWV), a provider of non-invasive wound care solutions, has been selected for inclusion in the Russell 2000® Index as part of the 2025 Russell indexes reconstitution, effective June 30. The company will also be included in the broader Russell 3000® Index and Russell Microcap® Index.

The Russell indexes, which capture the 4,000 largest U.S. stocks by market capitalization, are widely used by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked to these indexes as of June 2024. Membership in these indexes remains in place for one year.

Sanuwave Health specializes in regenerative medicine products for wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions through their patented energy transfer technologies.

Sanuwave Health (NASDAQ:SNWV) has appointed Greg Bazar to its Board of Directors. Bazar brings extensive experience in engineering, computer science, cybersecurity, AI, and business intelligence. He currently serves as Chairman of Simpatico Systems and was previously instrumental at 3D-P, leading to its acquisition by Epiroc. The appointment comes as board member Michael Stolarski steps down, though he will remain as a consultant to assist with the transition.

Bazar's appointment aligns with Sanuwave's focus on interdisciplinary leadership and its evolution beyond therapeutics into informational ecosystems. His background in technology and cybersecurity is expected to contribute to the company's future roadmap in wound care solutions.

Sanuwave Health (NASDAQ: SNWV) reported strong Q1 2025 financial results with record-breaking quarterly performance. Revenue reached $9.3 million, up 61% from Q1 2024, exceeding guidance of 45-55% growth. The company's gross margin improved to 79.0% from 72.6% year-over-year. UltraMist® system sales increased to 98 units (up 128% YoY), while consumables revenue grew 43% to $5.8 million. The company achieved operating income of $1.0 million, a $2.0 million improvement from Q1 2024. Adjusted EBITDA was $2.3 million compared to -$59,000 in Q1 2024. Despite operational improvements, net loss was $5.7 million due to derivative liabilities. Looking ahead, Sanuwave forecasts Q2 2025 revenue of $10.0-10.7 million (40-50% YoY growth) and maintains full-year 2025 guidance of $48-50 million.

Sanuwave Health (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, has scheduled a conference call to discuss their Q1 2025 financial results on Friday, May 9, 2025, at 8:30 AM ET.

Investors can access the call through toll-free (1-800-245-3047) or international (1-203-518-9765) numbers using Conference ID: SANUWAVE. Materials will be available on the company's investor website, and a replay will be accessible until May 30, 2025, using the replay access ID: 11158734.

SANUWAVE Health (NASDAQ: SNWV) reported preliminary Q1 2025 revenues of $9.1-9.3 million, marking the highest Q1 revenue in company history. This represents a 57-61% increase compared to Q1 2024.

The company's UltraMIST product line showed exceptional performance with a 65% growth versus Q1 2024, contributing to approximately 99% of total revenues. The strong performance came despite a transition period involving new sales leadership and sales force restructuring.

The company manufactures all UltraMIST systems and applicators domestically, insulating it from current tariff concerns. Full Q1 2025 results are expected to be released around May 9, 2025.